As of 2026-02-15, the EV/EBITDA ratio of Nektar Therapeutics (NKTR) is -6.32. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NKTR's latest enterprise value is 852.33 mil USD. NKTR's TTM EBITDA according to its financial statements is -134.93 mil USD. Dividing these 2 quantities gives us the above NKTR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.3x - 16.4x | 12.4x |
| Forward P/E multiples | 13.9x - 16.1x | 15.7x |
| Fair Price | (136.64) - (158.29) | (137.75) |
| Upside | -305.9% - -338.6% | -307.6% |
| Date | EV/EBITDA |
| 2026-02-12 | -6.55 |
| 2026-02-11 | -6.32 |
| 2026-02-10 | -5.28 |
| 2026-02-09 | -3.40 |
| 2026-02-06 | -3.37 |
| 2026-02-05 | -3.20 |
| 2026-02-04 | -3.45 |
| 2026-02-03 | -3.57 |
| 2026-02-02 | -3.50 |
| 2026-01-30 | -3.42 |
| 2026-01-29 | -3.21 |
| 2026-01-28 | -3.28 |
| 2026-01-27 | -3.49 |
| 2026-01-26 | -3.41 |
| 2026-01-23 | -3.40 |
| 2026-01-22 | -3.34 |
| 2026-01-21 | -3.38 |
| 2026-01-20 | -3.31 |
| 2026-01-16 | -3.46 |
| 2026-01-15 | -3.22 |
| 2026-01-14 | -3.30 |
| 2026-01-13 | -3.35 |
| 2026-01-12 | -3.56 |
| 2026-01-09 | -3.66 |
| 2026-01-08 | -3.83 |
| 2026-01-07 | -4.04 |
| 2026-01-06 | -3.98 |
| 2026-01-05 | -4.13 |
| 2026-01-02 | -4.03 |
| 2025-12-31 | -3.92 |
| 2025-12-30 | -3.88 |
| 2025-12-29 | -3.96 |
| 2025-12-26 | -4.14 |
| 2025-12-24 | -4.08 |
| 2025-12-23 | -4.13 |
| 2025-12-22 | -4.03 |
| 2025-12-19 | -4.37 |
| 2025-12-18 | -4.09 |
| 2025-12-17 | -4.23 |
| 2025-12-16 | -4.60 |
| 2025-12-15 | -5.01 |
| 2025-12-12 | -5.15 |
| 2025-12-11 | -4.80 |
| 2025-12-10 | -5.46 |
| 2025-12-09 | -5.56 |
| 2025-12-08 | -5.41 |
| 2025-12-05 | -5.37 |
| 2025-12-04 | -5.45 |
| 2025-12-03 | -5.40 |
| 2025-12-02 | -5.17 |